Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kevin Grogan

Managing Editor

London, UK

Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.

Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.

Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.

Writes for:

Latest From Kevin Grogan

Investors Animated Over Aclaris Oral Rheumatoid Arthritis Therapy

Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.

Immune Disorders Clinical Trials

The Top Five (Non-COVID) Pharma Stories Of 2020

The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.

M & A Companies

RedHill On The Rise With Three Drugs And Potential COVID-19 Therapy

The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.

Coronavirus COVID-19 Strategy

DBV Soars As Path For Peanut Allergy Patch Approval Clears

The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.

Immune Disorders Drug Review

Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor

Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.

Deals Business Strategies

Bayer Puts Spotlight On Pharma Pipeline

The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.

Gene Therapy Strategy
See All
UsernamePublicRestriction

Register